The Burden of Menstrual Migraine: Advances in diagnosis, treatment, and understanding of pathogenesis
DOI:
https://doi.org/10.12775/JEHS.2025.81.60098Keywords
menstrual migraine, acute treatment, prevention, triptans, CGRP antibodies, hormonal therapy, acupunctureAbstract
Menstrual migraine is a debilitating neurological condition linked to hormonal fluctuations during the menstrual cycle. It disproportionately affects women of reproductive age, imposing significant personal and societal burdens. Characterized by intense, prolonged headaches often resistant to standard treatments, menstrual migraines are primarily triggered by estrogen withdrawal and further influenced by prostaglandins and neurotransmitter dysregulation. This review synthesizes current knowledge on the pathophysiology of menstrual migraine, emphasizing hormonal and genetic factors, and highlights diagnostic criteria distinguishing pure menstrual migraine from menstrually related migraine.
The review examines both acute and chronic treatment approaches. Pharmacological options such as triptans, NSAIDs, and the emerging use of CGRP inhibitors and lasmiditan show varying levels of efficacy, while hormonal therapies aim to stabilize estrogen fluctuations. Non-pharmacological strategies, including lifestyle modifications, cognitive-behavioral therapy, and acupuncture, offer complementary relief and improve quality of life. Despite advancements, significant challenges remain, including variability in treatment response and a lack of biomarkers for precise diagnosis and management.
Furthermore, this review highlights gaps in current research, such as the need to better understand hormonal sensitivity and long-term treatment safety. Future directions emphasize the development of personalized therapies, innovative diagnostic tools, and more inclusive studies addressing the socioeconomic burden of menstrual migraines. By bridging these gaps, the medical community can advance care for affected women, reducing disability and improving overall well-being.
References
1. Aguilar-Shea AL, Membrilla Md JA, Diaz-de-Teran J. Migraine review for general
practice. Aten Primaria. 2022 Feb;54(2):102208. doi: 10.1016/j.aprim.2021.102208.
Epub 2021 Nov 16. PMID: 34798397; PMCID: PMC8605054.
2. Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features,
and pathophysiology of migraine. Lancet Neurol. 2017 Jan;16(1):76-87. doi:
10.1016/S1474-4422(16)30293-9. Epub 2016 Nov 9. PMID: 27836433.
3. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z; Lifting The Burden: the
Global Campaign against Headache. Migraine remains second among the world's
causes of disability, and first among young women: findings from GBD2019. J
Headache Pain. 2020 Dec 2;21(1):137. doi: 10.1186/s10194-020-01208-0. PMID:
33267788; PMCID: PMC7708887.
4. Ashina M, Terwindt GM, Al-Karagholi MA, de Boer I, Lee MJ, Hay DL, Schulte LH,
Hadjikhani N, Sinclair AJ, Ashina H, Schwedt TJ, Goadsby PJ. Migraine: disease
characterisation, biomarkers, and precision medicine. Lancet. 2021 Apr
17;397(10283):1496-1504. doi: 10.1016/S0140-6736(20)32162-0. Epub 2021 Mar 25.
PMID: 33773610.
5. Lucas C. Migraine with aura. Rev Neurol (Paris). 2021 Sep;177(7):779-784. doi:
10.1016/j.neurol.2021.07.010. Epub 2021 Aug 9. PMID: 34384631.
6. Olson AK, Hansen KA. Menstrual Migraines: Diagnosis, Evidence, and Treatment. S
D Med. 2021 Dec;74(12):570-575. PMID: 35015948.
7. Raffaelli B, Do TP, Chaudhry BA, Ashina M, Amin FM, Ashina H. Menstrual
migraine is caused by estrogen withdrawal: revisiting the evidence. J Headache Pain.
2023 Sep 21;24(1):131. doi: 10.1186/s10194-023-01664-4. PMID: 37730536;
PMCID: PMC10512516.
8. Nappi RE, Tiranini L, Sacco S, De Matteis E, De Icco R, Tassorelli C. Role of
Estrogens in Menstrual Migraine. Cells. 2022 Apr 15;11(8):1355. doi:
10.3390/cells11081355. PMID: 35456034; PMCID: PMC9025552.
9. Barra M, Dahl FA, MacGregor EA, Vetvik KG. Identifying menstrual migraine-
improving the diagnostic criteria using a statistical method. J Headache Pain. 2019
Sep 6;20(1):95. doi: 10.1186/s10194-019-1035-7. PMID: 31492101; PMCID:
PMC6734306.
10. Verhagen IE, Spaink HA, van der Arend BW, van Casteren DS,
MaassenVanDenBrink A, Terwindt GM. Validation of diagnostic ICHD-3 criteria for
menstrual migraine. Cephalalgia. 2022 Oct;42(11-12):1184-1193. doi:
10.1177/03331024221099031. Epub 2022 May 6. PMID: 35514214; PMCID:
PMC9535967.
11. Petrovski BÉ, Vetvik KG, Lundqvist C, Eberhard-Gran M. Characteristics of
menstrual versus non-menstrual migraine during pregnancy: a longitudinal
population-based study. J Headache Pain. 2018 Apr 2;19(1):27. doi: 10.1186/s10194-
018-0853-3. PMID: 29611008; PMCID: PMC5880793.
12. Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ.
Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine:
A Systematic Review and Meta-analysis. JAMA Netw Open. 2021 Oct
1;4(10):e2128544. doi: 10.1001/jamanetworkopen.2021.28544. PMID: 34633423;
PMCID: PMC8506232.
13. Ong JJY, De Felice M. Migraine Treatment: Current Acute Medications and Their
Potential Mechanisms of Action. Neurotherapeutics. 2018 Apr;15(2):274-290. doi:
10.1007/s13311-017-0592-1. Erratum in: Neurotherapeutics. 2018 Apr;15(2):525-
526. doi: 10.1007/s13311-017-0599-7. PMID: 29235068; PMCID: PMC5935632.
14. Khoo CC, Liu CC, Lu M, Huang YC, Weng HY. Acute and preventive treatment of
menstrual migraine: a meta-analysis. J Headache Pain. 2024 Sep 4;25(1):143. doi:
10.1186/s10194-024-01848-6. PMID: 39227797; PMCID: PMC11373287.
15. Doty EG, Krege JH, Jin L, Raskin J, Halker Singh RB, Kalidas K. Sustained
responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized
clinical trials for acute treatment of migraine. Cephalalgia. 2019 Oct;39(12):1569-
1576. doi: 10.1177/0333102419859313. Epub 2019 Jul 3. PMID: 31266353; PMCID:
PMC6791026.
16. Liu L, Zhang CS, Liu HL, He F, Lyu TL, Zeng L, Zhao LP, Wang MN, Qu ZY, Nie
LM, Guo J, Zhang XZ, Lu YH, Wang KL, Li B, Jing XH, Wang LP. Acupuncture for
menstruation-related migraine prophylaxis: A multicenter randomized controlled trial.
Front Neurosci. 2022 Aug 26;16:992577. doi: 10.3389/fnins.2022.992577. PMID:
36090267; PMCID: PMC9459087.
17. Bae JY, Sung HK, Kwon NY, Go HY, Kim TJ, Shin SM, Lee S. Cognitive
Behavioral Therapy for Migraine Headache: A Systematic Review and Meta-
Analysis. Medicina (Kaunas). 2021 Dec 28;58(1):44. doi:
10.3390/medicina58010044. PMID: 35056352; PMCID: PMC8777662.
18. Reddy N, Desai MN, Schoenbrunner A, Schneeberger S, Janis JE. The complex
relationship between estrogen and migraines: a scoping review. Syst Rev. 2021 Mar
10;10(1):72. doi: 10.1186/s13643-021-01618-4. PMID: 33691790; PMCID:
PMC7948327.
19. Creinin MD, Cagnacci A, Spaczyński RZ, Stute P, Chabbert-Buffet N, Korver T,
Simoncini T. Experts' view on the role of oestrogens in combined oral contraceptives:
emphasis on oestetrol (E4). Front Glob Womens Health. 2024 Apr 9;5:1395863. doi:
10.3389/fgwh.2024.1395863. PMID: 38655395; PMCID: PMC11035732.
20. Godley F 3rd, Meitzen J, Nahman-Averbuch H, O'Neal MA, Yeomans D, Santoro N,
Riggins N, Edvinsson L. How Sex Hormones Affect Migraine: An Interdisciplinary
Preclinical Research Panel Review. J Pers Med. 2024 Feb 7;14(2):184. doi:
10.3390/jpm14020184. PMID: 38392617; PMCID: PMC10889915.
21. Draper CF, Duisters K, Weger B, Chakrabarti A, Harms AC, Brennan L, Hankemeier
T, Goulet L, Konz T, Martin FP, Moco S, van der Greef J. Menstrual cycle
rhythmicity: metabolic patterns in healthy women. Sci Rep. 2018 Oct 1;8(1):14568.
doi: 10.1038/s41598-018-32647-0. Erratum in: Sci Rep. 2019 Apr 3;9(1):5797. doi:
10.1038/s41598-019-41392-x. PMID: 30275458; PMCID: PMC6167362.
22. Vetvik KG, MacGregor EA. Menstrual migraine: a distinct disorder needing greater
recognition. Lancet Neurol. 2021 Apr;20(4):304-315. doi: 10.1016/S1474-
4422(20)30482-8. Epub 2021 Feb 15. PMID: 33600767.
23. Beech EL, Riddell N, Murphy MJ, Crewther SG. Sex and stress hormone
dysregulation as clinical manifestations of hypothalamic function in migraine
disorder: A meta-analysis. Eur J Neurosci. 2023 Aug;58(4):3150-3171. doi:
10.1111/ejn.16087. Epub 2023 Jul 15. PMID: 37452646.2005 Oct;45(9):1190-201.
doi: 10.1111/j.1526-4610.2005.00242.x. PMID: 16178949.
24. Paredes S, Cantillo S, Candido KD, Knezevic NN. An Association of Serotonin with
Pain Disorders and Its Modulation by Estrogens. Int J Mol Sci. 2019 Nov
15;20(22):5729. doi: 10.3390/ijms20225729. PMID: 31731606; PMCID:
PMC6888666.
25. Ethridge SB, Smith MA. Estradiol and Mu opioid-mediated reward: The role of
estrogen receptors in opioid use. Addict Neurosci. 2023 Dec 15;9:100139. doi:
10.1016/j.addicn.2023.100139. Epub 2023 Nov 25. PMID: 38155959; PMCID:
PMC10753849.
26. González SL, Meyer L, Raggio MC, Taleb O, Coronel MF, Patte-Mensah C, Mensah-
Nyagan AG. Allopregnanolone and Progesterone in Experimental Neuropathic Pain:
Former and New Insights with a Translational Perspective. Cell Mol Neurobiol. 2019
May;39(4):523-537. doi: 10.1007/s10571-018-0618-1. Epub 2018 Sep 5. PMID:
30187261.
27. DeFazio RA, Navarro MA, Adams CE, Milescu LS, Moenter SM. Estradiol Enhances
the Depolarizing Response to GABA and AMPA Synaptic Conductances in Arcuate
Kisspeptin Neurons by Diminishing Voltage-Gated Potassium Currents. J Neurosci.
2019 Nov 27;39(48):9532-9545. doi: 10.1523/JNEUROSCI.0378-19.2019. Epub
2019 Oct 18. PMID: 31628184; PMCID: PMC6880461.
28. Goyette MJ, Murray SL, Saldanha CJ, Holton K. Sex Hormones, Neurosteroids, and
Glutamatergic Neurotransmission: A Review of the Literature. Neuroendocrinology.
2023;113(9):905-914. doi: 10.1159/000531148. Epub 2023 May 20. PMID:
37232008.
29. Warfvinge K, Krause DN, Maddahi A, Edvinsson JCA, Edvinsson L, Haanes KA.
Estrogen receptors α, β and GPER in the CNS and trigeminal system - molecular and
functional aspects. J Headache Pain. 2020 Nov 10;21(1):131. doi: 10.1186/s10194-
020-01197-0. PMID: 33167864; PMCID: PMC7653779.
30. Edvinsson L. CGRP and migraine: from bench to bedside. Rev Neurol (Paris). 2021
Sep;177(7):785-790. doi: 10.1016/j.neurol.2021.06.003. Epub 2021 Jul 15. PMID:
34275653.
31. Maasumi K, Michael RL, Rapoport AM. CGRP and Migraine: The Role of Blocking
Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of
Migraine. Drugs. 2018 Jun;78(9):913-928. doi: 10.1007/s40265-018-0923-5. PMID:
29869205.
32. Kuburas A, Russo AF. Shared and independent roles of CGRP and PACAP in
migraine pathophysiology. J Headache Pain. 2023 Apr 3;24(1):34. doi:
10.1186/s10194-023-01569-2. PMID: 37009867; PMCID: PMC10069045.
33. de Vries Lentsch S, Rubio-Beltrán E, MaassenVanDenBrink A. Changing levels of
sex hormones and calcitonin gene-related peptide (CGRP) during a woman's life:
Implications for the efficacy and safety of novel antimigraine medications. Maturitas.
2021 Mar;145:73-77. doi: 10.1016/j.maturitas.2020.12.012. Epub 2021 Jan 6. PMID:
33541566.
34. Noseda R, Bedussi F, Gobbi C, Ceschi A, Zecca C. Safety profile of monoclonal
antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated
analysis in VigiBase®. Cephalalgia. 2023 Apr;43(4):3331024231158083. doi:
10.1177/03331024231158083. PMID: 36855950.
35. Raffaelli B, Storch E, Overeem LH, Terhart M, Fitzek MP, Lange KS, Reuter U. Sex
Hormones and Calcitonin Gene-Related Peptide in Women With Migraine: A Cross-
sectional, Matched Cohort Study. Neurology. 2023 Apr 25;100(17):e1825-e1835. doi:
10.1212/WNL.0000000000207114. Epub 2023 Feb 22. PMID: 36813730; PMCID:
PMC10136010.
36. Oliveira MA, Lima WG, Schettini DA, Tilelli CQ, Chaves VE. Is calcitonin gene-
related peptide a modulator of menopausal vasomotor symptoms? Endocrine. 2019
Feb;63(2):193-203. doi: 10.1007/s12020-018-1777-z. Epub 2018 Oct 10. PMID:
30306319.
37. Guimarães I, Póvoa AM. Primary Dysmenorrhea: Assessment and Treatment. Rev
Bras Ginecol Obstet. 2020 Aug;42(8):501-507. doi: 10.1055/s-0040-1712131. Epub
2020 Jun 19. PMID: 32559803; PMCID: PMC10309238.
38. Abreu-Sánchez A, Parra-Fernández ML, Onieva-Zafra MD, Ramos-Pichardo JD,
Fernández-Martínez E. Type of Dysmenorrhea, Menstrual Characteristics and
Symptoms in Nursing Students in Southern Spain. Healthcare (Basel). 2020 Aug
26;8(3):302. doi: 10.3390/healthcare8030302. PMID: 32858887; PMCID:
PMC7551507.
39. Spierings EL, Padamsee A. Menstrual-Cycle and Menstruation Disorders in Episodic
vs Chronic Migraine: An Exploratory Study. Pain Med. 2015 Jul;16(7):1426-32. doi:
10.1111/pme.12788. Epub 2015 Apr 30. PMID: 25930018.
40. Harder AVE, Onderwater GLJ, van Dongen RM, Heijink M, van Zwet EW, Giera M,
van den Maagdenberg AMJM, Terwindt GM. Prostaglandin-E2 levels over the course
of glyceryl trinitrate provoked migraine attacks. Neurobiol Pain. 2022 Dec
28;13:100112. doi: 10.1016/j.ynpai.2022.100112. PMID: 36636095; PMCID:
PMC9829921.
41. van der Vaart JF, Merki-Feld GS. Sex hormone-related polymorphisms in
endometriosis and migraine: A narrative review. Womens Health (Lond). 2022 Jan-
Dec;18:17455057221111315. doi: 10.1177/17455057221111315. PMID: 35848345;
PMCID: PMC9290099.
42. Kalarani IB, Mohammed V, Veerabathiran R. Genetics of Menstrual Migraine and
Their Association with Female Hormonal Factors. Ann Indian Acad Neurol. 2022
May-Jun;25(3):383-388. doi: 10.4103/aian.aian_1116_21. Epub 2022 May 3. PMID:
35936591; PMCID: PMC9350771.
43. Pollock CE, Sutherland HG, Maher BH, Lea RA, Haupt LM, Frith A, Anne
MacGregor E, Griffiths LR. The NRP1 migraine risk variant shows evidence of
association with menstrual migraine. J Headache Pain. 2018 Apr 18;19(1):31. doi:
10.1186/s10194-018-0857-z. PMID: 29671086; PMCID: PMC5906416.
44. Headache Classifcation Committee of the International Headache Society (IHS)
(2018) The international classifcation of headache disorders, 3rd edition. Cephalalgia
38:1–211
45. Ashina S, Mitsikostas DD, Lee MJ, Yamani N, Wang SJ, Messina R, Ashina H, Buse
DC, Pozo-Rosich P, Jensen RH, Diener HC, Lipton RB. Tension-type headache. Nat
Rev Dis Primers. 2021 Mar 25;7(1):24. doi: 10.1038/s41572-021-00257-2. PMID:
33767185.
46. Ansari T, Lagman-Bartolome AM, Monsour D, Lay C. Management of Menstrual
Migraine. Curr Neurol Neurosci Rep. 2020 Aug 8;20(10):45. doi: 10.1007/s11910-
020-01067-x. PMID: 32770368.
47. Kung D, Rodriguez G, Evans R. Chronic Migraine: Diagnosis and Management.
Neurol Clin. 2023 Feb;41(1):141-159. doi: 10.1016/j.ncl.2022.05.005. Epub 2022 Oct
31. PMID: 36400552.
48. Riley CA, Navarro AI, Trinh L, Abuzeid WM, Humphreys IM, Akbar NA, Shah S,
Lee JT, Wu T, Schneider JS, Tolisano AM, McCoul ED. What do we mean when we
have a "sinus infection?". Int Forum Allergy Rhinol. 2023 Feb;13(2):129-139. doi:
10.1002/alr.23063. Epub 2022 Jul 24. PMID: 35841605.
49. Delaruelle Z, Ivanova TA, Khan S, Negro A, Ornello R, Raffaelli B, Terrin A,
Mitsikostas DD, Reuter U; European Headache Federation School of Advanced
Studies (EHF-SAS). Male and female sex hormones in primary headaches. J
Headache Pain. 2018 Nov 29;19(1):117. doi: 10.1186/s10194-018-0922-7. PMID:
30497379; PMCID: PMC6755575.
50. Bates NJ, Garvick SJ. Cluster headaches. JAAPA. 2023 Jul 1;36(7):44-45. doi:
10.1097/01.JAA.0000937284.43206.12. PMID: 37368853.
51. Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C, Schwedt TJ,
Jensen RH, Diener HC, Lipton RB. Medication overuse headache. Nat Rev Dis
Primers. 2023 Feb 2;9(1):5. doi: 10.1038/s41572-022-00415-0. PMID: 36732518.
52. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z; Lifting The Burden: the
Global Campaign against Headache. Migraine remains second among the world's
causes of disability, and first among young women: findings from GBD2019. J
Headache Pain. 2020 Dec 2;21(1):137. doi: 10.1186/s10194-020-01208-0. PMID:
33267788; PMCID: PMC7708887.
53. Snoer AH, Høst C, Dømgaard M, Hansen JM. Frequent or chronic migraine
negatively impacts personal, social and professional life. Dan Med J. 2021 Oct
2;68(11):A08200592. PMID: 34983726.
54. Law HZ, Chung MH, Nissan G, Janis JE, Amirlak B. Hospital Burden of Migraine in
United States Adults: A 15-year National Inpatient Sample Analysis. Plast Reconstr
Surg Glob Open. 2020 Apr 23;8(4):e2790. doi: 10.1097/GOX.0000000000002790.
PMID: 32440450; PMCID: PMC7209847.
55. Ornello R, De Matteis E, Di Felice C, Caponnetto V, Pistoia F, Sacco S. Acute and
Preventive Management of Migraine during Menstruation and Menopause. J Clin
Med. 2021 May 24;10(11):2263. doi: 10.3390/jcm10112263. PMID: 34073696;
PMCID: PMC8197159.
56. Peck J, Urits I, Zeien J, Hoebee S, Mousa M, Alattar H, Kaye AD, Viswanath O. A
Comprehensive Review of Over-the-counter Treatment for Chronic Migraine
Headaches. Curr Pain Headache Rep. 2020 Mar 21;24(5):19. doi: 10.1007/s11916-
020-00852-0. PMID: 32200435.
57. Nicolas S, Nicolas D. Triptans. 2024 Feb 25. In: StatPearls [Internet]. Treasure Island
(FL): StatPearls Publishing; 2024 Jan–. PMID: 32119394.
58. Allais G, Chiarle G, Sinigaglia S, Benedetto C. Menstrual migraine: a review of
current and developing pharmacotherapies for women. Expert Opin Pharmacother.
2018 Feb;19(2):123-136. doi: 10.1080/14656566.2017.1414182. Epub 2017 Dec 12.
PMID: 29212383.
59. Ceriani CEJ, Silberstein SD. Current and emerging pharmacotherapy for menstrual
migraine: a narrative review. Expert Opin Pharmacother. 2023 Apr;24(5):617-627.
doi: 10.1080/14656566.2023.2194487. Epub 2023 Mar 23. PMID: 36946205.
60. Khoo CC, Liu CC, Lu M, Huang YC, Weng HY. Acute and preventive treatment of
menstrual migraine: a meta-analysis. J Headache Pain. 2024 Sep 4;25(1):143. doi:
10.1186/s10194-024-01848-6. PMID: 39227797; PMCID: PMC11373287.
61. Wilcha RJ, Afridi SK, Barbanti P, Diener HC, Jürgens TP, Lanteri-Minet M, Lucas C,
Mawet J, Moisset X, Russo A, Sacco S, Sinclair AJ, Sumelahti ML, Tassorelli C,
Goadsby PJ. Sumatriptan-naproxen sodium in migraine: A review. Eur J Neurol. 2024
Sep;31 Suppl 2(Suppl 2):e16434. doi: 10.1111/ene.16434. PMID: 39318200; PMCID:
PMC11422667.
62. Kazi F, Manyapu M, Fakherddine M, Mekuria K, Friedman BW. Second-line
interventions for migraine in the emergency department: A narrative review.
Headache. 2021 Nov;61(10):1467-1474. doi: 10.1111/head.14239. Epub 2021 Nov
22. PMID: 34806767.
63. MacGregor EA, Komori M, Krege JH, Baygani S, Vincent M, Pavlovic J, Igarashi H.
Efficacy of lasmiditan for the acute treatment of perimenstrual migraine. Cephalalgia.
2022 Dec;42(14):1467-1475. doi: 10.1177/03331024221118929. Epub 2022 Aug 18.
PMID: 35979677; PMCID: PMC9693902.
64. MacGregor EA, Hutchinson S, Lai H, Dabruzzo B, Yu SY, Trugman JM, Ailani J.
Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine
attacks: A post hoc analysis. Headache. 2023 Sep;63(8):1135-1144. doi:
10.1111/head.14619. Epub 2023 Sep 1. PMID: 37655536.
65. Blair HA. Rimegepant: A Review in the Acute Treatment and Preventive Treatment
of Migraine. CNS Drugs. 2023 Mar;37(3):255-265. doi: 10.1007/s40263-023-00988-
8. Epub 2023 Feb 4. Erratum in: CNS Drugs. 2023 Jul;37(7):661. doi:
10.1007/s40263-023-01019-2. PMID: 36739335; PMCID: PMC10299922.
66. Lebedeva ER. Sex and age differences in migraine treatment and management
strategies. Int Rev Neurobiol. 2022;164:309-347. doi: 10.1016/bs.irn.2022.07.003.
Epub 2022 Aug 10. PMID: 36038208.
67. Al-Hassany L, Haas J, Piccininni M, Kurth T, Maassen Van Den Brink A, Rohmann
JL. Giving Researchers a Headache - Sex and Gender Differences in Migraine. Front
Neurol. 2020 Oct 22;11:549038. doi: 10.3389/fneur.2020.549038. PMID: 33192977;
PMCID: PMC7642465.
68. Nishihara C, Hatori K, Hsu YC, Ozasa K, Young A, Imamura Y, Noma N. Orofacial
Pain and Menstrually Related Migraine. Acta Neurol Taiwan. 2019 Dec 15;28(4):131-
138. PMID: 32026457.
69. Pavlovic JM, Paemeleire K, Göbel H, Bonner J, Rapoport A, Kagan R, Zhang F,
Picard H, Mikol DD. Efficacy and safety of erenumab in women with a history of
menstrual migraine. J Headache Pain. 2020 Aug 3;21(1):95. doi: 10.1186/s10194-
020-01167-6. PMID: 32746775; PMCID: PMC7398400.
70. Igarashi H, Shibata M, Ozeki A, Matsumura T. Galcanezumab Effects on Migraine
Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary
Analysis of a Phase 2 Randomized Trial. Neurol Ther. 2023 Feb;12(1):73-87. doi:
10.1007/s40120-022-00410-3. Epub 2022 Oct 20. PMID: 36266558; PMCID:
PMC9837349.
71. MacGregor EA, Okonkwo R, Detke HC, Polavieja P, Fernandes MS, Pavlovic JM.
Effect of galcanezumab in women with episodic migraine meeting criteria for
menstrually related migraine: A post hoc analysis of EVOLVE-1 and EVOLVE-2.
Headache. 2024 Feb;64(2):179-187. doi: 10.1111/head.14652. Epub 2023 Nov 28.
PMID: 38017629.
72. Merki-Feld GS, Caveng N, Speiermann G, MacGregor EA. Migraine start, course and
features over the cycle of combined hormonal contraceptive users with menstrual
migraine - temporal relation to bleeding and hormone withdrawal: a prospective
diary-based study. J Headache Pain. 2020 Jun 24;21(1):81. doi: 10.1186/s10194-020-
01150-1. PMID: 32580694; PMCID: PMC7315546.
73. Sacco S, Merki-Feld GS, Ægidius KL, Bitzer J, Canonico M, Gantenbein AR, Kurth
T, Lampl C, Lidegaard Ø, Anne MacGregor E, MaassenVanDenBrink A, Mitsikostas
DD, Nappi RE, Ntaios G, Paemeleire K, Sandset PM, Terwindt GM, Vetvik KG,
Martelletti P; European Headache Federation (EHF), the European Society of
Contraception and Reproductive Health (ESCRH). Effect of exogenous estrogens and
progestogens on the course of migraine during reproductive age: a consensus
statement by the European Headache Federation (EHF) and the European Society of
Contraception and Reproductive Health (ESCRH). J Headache Pain. 2018 Aug
31;19(1):76. doi: 10.1186/s10194-018-0896-5. PMID: 30171365; PMCID:
PMC6119173.
74. Teal S, Edelman A. Contraception Selection, Effectiveness, and Adverse Effects: A
Review. JAMA. 2021 Dec 28;326(24):2507-2518. doi: 10.1001/jama.2021.21392.
PMID: 34962522.
75. Warhurst S, Rofe CJ, Brew BJ, Bateson D, McGeechan K, Merki-Feld GS, Garrick R,
Tomlinson SE. Effectiveness of the progestin-only pill for migraine treatment in
women: A systematic review and meta-analysis. Cephalalgia. 2018 Apr;38(4):754-
764. doi: 10.1177/0333102417710636. Epub 2017 May 29. PMID: 28554244.
76. Reddy N, Desai MN, Schoenbrunner A, Schneeberger S, Janis JE. The complex
relationship between estrogen and migraines: a scoping review. Syst Rev. 2021 Mar
10;10(1):72. doi: 10.1186/s13643-021-01618-4. PMID: 33691790; PMCID:
PMC7948327.
77. MacGregor EA. Migraine, menopause and hormone replacement therapy. Post
Reprod Health. 2018 Mar;24(1):11-18. doi: 10.1177/2053369117731172. Epub 2017
Oct 10. PMID: 28994639.
78. Burch R. Preventive Migraine Treatment. Continuum (Minneap Minn). 2021 Jun
1;27(3):613-632. doi: 10.1212/CON.0000000000000957. Erratum in: Continuum
(Minneap Minn). 2021 Oct 1;27(5):1494-1495. doi:
10.1212/CON.0000000000001085. PMID: 34048395.
79. Li YX, Xiao XL, Zhong DL, Luo LJ, Yang H, Zhou J, He MX, Shi LH, Li J, Zheng
H, Jin RJ. Effectiveness and Safety of Acupuncture for Migraine: An Overview of
Systematic Reviews. Pain Res Manag. 2020 Mar 23;2020:3825617. doi:
10.1155/2020/3825617. PMID: 32269669; PMCID: PMC7125485.
80. Natbony LR, Zhang N. Acupuncture for Migraine: a Review of the Data and Clinical
Insights. Curr Pain Headache Rep. 2020 May 29;24(7):32. doi: 10.1007/s11916-020-
00864-w. PMID: 32472196.
81. Lin JG, Kotha P, Chen YH. Understandings of acupuncture application and
mechanisms. Am J Transl Res. 2022 Mar 15;14(3):1469-1481. PMID: 35422904;
PMCID: PMC8991130.
82. Wu Q, Wang J, Lin X, Han D, Hu H, Gao H. Determining the Efficacy and Safety of
Acupuncture for the Preventive Treatment of Menstrual Migraine: A Protocol for a
PRISMA-Compliant Systematic Review and Meta-Analysis. J Pain Res. 2023 Jan
10;16:101-109. doi: 10.2147/JPR.S394446. PMID: 36647433; PMCID:
PMC9840396.
83. Liu L, Zhang CS, Liu HL, He F, Lyu TL, Zeng L, Zhao LP, Wang MN, Qu ZY, Nie
LM, Guo J, Zhang XZ, Lu YH, Wang KL, Li B, Jing XH, Wang LP. Acupuncture for
menstruation-related migraine prophylaxis: A multicenter randomized controlled trial.
Front Neurosci. 2022 Aug 26;16:992577. doi: 10.3389/fnins.2022.992577. PMID:
36090267; PMCID: PMC9459087.
84. Yang M, Du T, Long H, Sun M, Liang F, Lao L. Acupuncture for menstrual migraine:
a systematic review. BMJ Support Palliat Care. 2022 Dec;12(e6):e882-e892. doi:
10.1136/bmjspcare-2019-002024. Epub 2020 Mar 2. PMID: 32122964; PMCID:
PMC9726974.
85. Zhang Y, Wang Z, Du J, Liu J, Xu T, Wang X, Sun M, Wen Y, Li D, Liao H, Zhao Y,
Zhao L. Regulatory Effects of Acupuncture on Emotional Disorders in Patients With
Menstrual Migraine Without Aura: A Resting-State fMRI Study. Front Neurosci.
2021 Oct 4;15:726505. doi: 10.3389/fnins.2021.726505. PMID: 34671239; PMCID:
PMC8521095.
86. Bae JY, Sung HK, Kwon NY, Go HY, Kim TJ, Shin SM, Lee S. Cognitive
Behavioral Therapy for Migraine Headache: A Systematic Review and Meta-
Analysis. Medicina (Kaunas). 2021 Dec 28;58(1):44. doi:
10.3390/medicina58010044. PMID: 35056352; PMCID: PMC8777662.
87. Minen MT, George A, Cuneo AZ. Factors Associated with Patient Adherence to
Biofeedback Therapy Referral for Migraine: An Observational Study. Appl
Psychophysiol Biofeedback. 2024 Jun;49(2):281-289. doi: 10.1007/s10484-024-
09622-9. Epub 2024 Feb 22. PMID: 38386246.
88. Agbetou M, Adoukonou T. Lifestyle Modifications for Migraine Management. Front
Neurol. 2022 Mar 18;13:719467. doi: 10.3389/fneur.2022.719467. PMID: 35370920;
PMCID: PMC8971279.
89. Gazerani P. Migraine and Diet. Nutrients. 2020 Jun 3;12(6):1658. doi:
10.3390/nu12061658. PMID: 32503158; PMCID: PMC7352457.
90. Annalisa G, Davide B, Marco A. Sport and migraine-a dynamic relationship. Neurol
Sci. 2022 Sep;43(9):5749-5751. doi: 10.1007/s10072-022-06273-8. Epub 2022 Jul 19.
PMID: 35852657.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Paulina Głogowska, Daria Furtak, Dawid Tulej, Alicja Dziedzic, Wiktor Grela, Jagoda Niewiadomska, Natalia Marko, Natalia Gniaź, Dominika Marciniuk, Aleksandra Górska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 242
Number of citations: 0
